GREAT 1st DAY OF #PROSCA24 Currently going on in Vienna🇦🇹 Perfect way to follow up 2 Amazing meetings in #RENALC24 @ #BLADDR24 w/ OVER 10 million impressions on X ‼️ Kudos to Mirrors of Medicine @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social
#PROSCA24 ✨PSMA is the imaging choice in BCR ✨impact on clinical management ~60% ✨PPV 85-90% ✨different PSMA tracers with different detection rate ✨PROMISE registry to build monogram to predict survival: in BCR setting the nomogram had a strong correlation with survival ‼️for MDT: use PSMA11
The OncoAlert Network 🚨@oncoalert.bsky.social · 2y agoDay One of #PROSCA24 Presenter: Dr Karolien Goffin Biochemical recurrence following ocal therapy PSMA-PET in BCR – what to expect? @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social
Day One of #PROSCA24 Presenter: Dr Alfred Haidenberger Biochemical recurrence following local therapy Radiosurgery for Recurrent Prostate Cancer @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social
One size doesn’t fit all‼️ ✨Improved RT delivery ✨ADT: consider life expectancy, baseline comorbidities ✨ADT duration: 18 months may be enough; genomic classifiers could better tailor duration ✨Intensification (ARPI) in very high-risk patients
The OncoAlert Network 🚨@oncoalert.bsky.social · 2y agoDay One of #PROSCA24 Dr Thomas Zilli High-risk localised/locally advanced PCa Combination of radiotherapy and systemic treatment for high-risk patients: not one size fits all @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social
Gleason 6: should we keep calling it cancer? Eva Compérat Yes‼️ It’s cancer ✨People may die from GS 6 ✨Up to 80% heterogeneous ✨We can not predict those who will progress ‼️Patient will be much more willing to be followed @oncoalert.bsky.social @drnataliagandur.bsky.social @yukselurun.bsky.social
Gleason 6: should we keep calling it cancer?Roderick van den Bergh No‼️ But we need surveillance ✨It doesn’t metastasize ✨14% upgrading ✨12-24% true progression ‼️Use of risk factors could estimate the risk of true cancer @oncoalert.bsky.social @drnataliagandur.bsky.social @yukselurun.bsky.social
#PROSCA24 livestream starting with ADT and cardiovascular risk in #ProstateCancer. Suma Konety ‼️ADT increases CV risk => development of metabolic syndrome ‼️Control of blood pressure and cholesterol is mandatory = high genomic diversity @oncoalert.bsky.social @drnataliagandur.bsky.social
Day One of #RENALC24 Dr. Philippe BARTHÉLÉMY Looking ahead: RCC management in 2025 Importance of precision medicine, optimization of combination therapies & need for new biomarkers to improve outcomes. #KidneyCancer @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social
2 Million Impressions on the first ever #RenalC24 Congratulations to our Collaborators at Mirrors of Medicine JOIN US TOMORROW for Day One of #BLADDR24 WE ARE @OncoAlert 🚨 @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social
Elucidating acquired PARP inh resistance sciencedirect.com/science/arti... Highlights emergence of resistance in met CR #ProstateCancer tx w/ PARP inh💊, particularly in BRCA2 & PALB2 mutations🧬 @drnataliagandur.bsky.social @barbaramelao.bsky.social @achoud72.bsky.social @yukselurun.bsky.social
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
PARP inhibition (PARPi) has anti-tumor activity against castration-resistant prostate cancer (CRPC) with homologous recombination repair (HRR) defects…
sciencedirect.com
Honored to be part of this team @oncoalert.bsky.social
The OncoAlert Network 🚨@oncoalert.bsky.social · 2y agoDear Colleagues A Pleasure to introduce some our #OncoAlertAF Associate Faculty 🚨 @elisaagostinetto.bsky.social 🇧🇪 @elisabettabonzano.bsky.social 🇮🇹 @realbowtiedoc.bsky.social 🇺🇸 @biagioricciutimd.bsky.social 🇺🇸 @weoncologists.bsky.social 🇺🇸 @drnataliagandur.bsky.social 🇦🇷
